Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Matrixyl 30007 residues (approx.)GHKGQPREach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: Pal-GHK + Pal-GQPR, Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7
Forty-five percent fewer deep wrinkles in two months. That's the headline from Sederma's double-blind trial of Matrixyl 3000, a patented dual-peptide complex pairing Palmitoyl Tripeptide-1 (Pal-GHK) with Palmitoyl Tetrapeptide-7 (Pal-GQPR). One peptide signals fibroblasts to build new collagen. The other shuts down the IL-6 inflammatory cascade that breaks collagen apart. Most pivotal trial data comes from the manufacturer (n=23), so independent confirmation at scale is still missing. Skincare communities on Reddit rate it 4 out of 5 across hundreds of threads, and it stacks cleanly with GHK-Cu, retinoids, and vitamin C without tolerance issues.
Does a cosmeceutical peptide actually reduce wrinkles by 45%? Sederma's double-blind RCT (n=23) produced that number at eight weeks of twice-daily 3% complex application. Matrixyl 3000 (CAS: mixture of Palmitoyl Tripeptide-1, MW 578.8 Da, and Palmitoyl Tetrapeptide-7, MW 694.9 Da; patent WO 2005/048968) is a dual-peptide topical complex designed to hit skin aging from two directions at once. The first component, Pal-GHK, shares its tripeptide backbone with GHK-Cu but carries a palmitic acid chain instead of copper. It mimics collagen breakdown fragments, and when fibroblasts detect those fragments, they ramp up production of collagen types I, III, IV, and VII along with fibronectin and glycosaminoglycans. The second component, Pal-GQPR, derived from an immunoglobulin G fragment, suppresses IL-6 secretion from keratinocytes. That tackles inflammaging, the chronic low-grade inflammation that upregulates matrix metalloproteinases and chews through existing collagen. In vitro, the combination pushed collagen I production up 117%, collagen IV up 327%, and glycosaminoglycan synthesis up 287% vs. controls. A 2024 independent eye cream RCT (n=30)[1] confirmed collagen mRNA upregulation across multiple types: Col I at 1.8x, Col III at 2.5x, Col IV at 2.8x, elastin at 5.0x, and fibronectin at 1.6x over 12 weeks. The honest assessment: evidence is moderate-strong for a cosmeceutical. Most important trials are manufacturer-sponsored with small sample sizes. No large independent blinded RCT for full-face application exists yet. The CIR Expert Panel confirmed safety at current cosmetic concentrations (Int J Toxicol 2018). Community experience across r/SkincareAddiction matches the clinical timeline closely, with users reporting visible wrinkle improvement at 6 to 8 weeks.
Matrixyl 3000 runs two complementary matrikine signaling pathways in a single complex. Understanding both explains why it outperforms single-peptide formulations. Palmitoyl Tripeptide-1 (Pal-GHK) is a lipidated fragment of type I collagen. It works through a feedback loop. When collagen breaks down in aging skin, the fragments signal fibroblasts to produce replacements. Pal-GHK mimics those fragments. It engages cell-surface integrins and triggers TGF-beta receptor signaling cascades that upregulate transcription of collagen I, III, IV, and VII genes. Fibronectin and glycosaminoglycan synthesis ramp up through the same pathway. Palmitoyl Tetrapeptide-7 (Pal-GQPR) targets inflammation instead. Derived from an immunoglobulin G fragment, it inhibits IL-6 release from UVB-stimulated keratinocytes and reduces NF-kB-mediated inflammatory signaling. Chronic inflammaging drives MMP expression; those matrix metalloproteinases degrade collagen faster than aging skin can replace it. By suppressing IL-6, Pal-GQPR protects existing collagen while Pal-GHK builds new fibers. Both peptides carry a 16-carbon palmitic acid chain conjugated at the N-terminus. That lipid tail dramatically increases lipophilicity, enabling penetration through the hydrophobic stratum corneum to reach target cells in the dermis. Without that palmitoyl modification, free peptides bounce off the skin's outer barrier.
Manufacturer-sponsored RCTs (Sederma) show 45% deep wrinkle reduction at 2 months and up to 68% at 6 months with twice-daily 3% complex application. 2024 independent eye cream RCT (n=30)[1] confirms collagen mRNA upregulation: Col I 1.8×, Col III 2.5×, Col IV 2.8×, elastin 5.0×, fibronectin 1.6×. In vitro: collagen I +117%, collagen IV +327%, GAG +287% vs. controls. CIR Expert Panel (Int J Toxicol 2018) confirms safety at cosmetic use concentrations (<10 ppm per peptide). ~60+ PubMed papers on Pal-GHK and Pal-GQPR separately. Evidence base is moderate-strong for topical anti-aging efficacy; most pivotal trials are Sederma-sponsored.
Sederma internal RCT: 3% complex cream, n=23, twice daily, 2 months: 45% reduction in deep wrinkle surface area, 17.1% wrinkle volume decrease, ~20% increase in skin tonicity. 6-month extension: 68% wrinkle surface reduction, 46% wrinkle density decrease. Independent 2024 eye cream RCT (PMID 38932444): n=30, 12 weeks: 54.99% collagen increase, 18.81% elasticity improvement.
Most pivotal efficacy trials are Sederma-sponsored with limited sample sizes (n=23–30). No large independent blinded RCT for full-face application exists. Individual peptide concentrations in finished products (<10 ppm each) are difficult for consumers to verify. Skin penetration depth relies on in vitro models; formal human dermal pharmacokinetics not established by peer-reviewed PK study. 2025 PMC review (PMC11762834) notes cosmeceutical peptide literature generally lacks standardized outcome measures.
Highly positive reception in r/SkincareAddiction and r/DIYBeauty. Consistently rated as a meaningful upgrade over single-peptide original Matrixyl, especially valued by users with oily or inflamed skin for the dual collagen+anti-inflammatory mechanism. Community sentiment 4/5.
Community-reported timelines (visible results at 6–8 weeks) closely match the 2-month Sederma clinical endpoint. Both agree on twice-daily application and ≥3% concentration as optimal. Community preference for the dual mechanism (collagen synthesis + anti-inflammatory) aligns with in vitro mechanistic data.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | Daily |
| Moderate | 5mg | 2x Daily |
| Aggressive | 10mg | 2x Daily |
This one is topical, so no vials, no syringes, no bacteriostatic water. You're shopping for a serum, not a lyophilized powder. The number that matters is complex concentration. Sederma's clinical data used 3% Matrixyl 3000 complex. Products that list "Matrixyl 3000" without disclosing the percentage probably contain too little to match clinical results. Look for palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 both appearing in the top 10 INCI ingredients; if they're near the bottom, the concentration is cosmetic-grade marketing rather than clinical-grade dosing. The Ordinary's Matrixyl 10% + HA lists 10% combined Matrixyl 3000 and Matrixyl Synthe'6 at about $15 for 30ml. That's transparent labeling. Paula's Choice Peptide Booster runs $58 for 20ml. Raw Sederma complex costs $80 to $200 per gram for DIY formulators. Apply to clean, dry skin. Wait 2 to 3 minutes before layering other products. If you're using GHK-Cu in the same routine, apply that first (lower molecular weight, faster absorption). Retinoid and Matrixyl 3000 work fine together but if your skin is sensitive, split them: Matrixyl AM, retinoid PM.
Apply twice daily for 16 weeks to allow full collagen remodeling. Manufacturer clinical data shows progressive improvement through 2-6 months of consistent use. The 2-week break is optional: no receptor desensitization has been documented, and many users apply continuously. Visible results typically begin at weeks 4-8 and continue accumulating through week 16+. Effects diminish gradually over several weeks after discontinuation.
No receptor desensitization, antibody formation, or hormonal axis recovery rationale applies. The 16 weeks on / 2 weeks off protocol in peptides.ts derives from Sederma's clinical study assessment endpoints (2-month and 6-month timepoints), not a documented pharmacological necessity. Continuous long-term use is practiced widely without evidence of diminishing efficacy or adverse effects from uninterrupted application. The break is optional and likely reflects the study design convention rather than any physiological requirement.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved skin hydration and texture by weeks 4–6; moderate fine line softening by week 16
Monitor: Photograph target areas (periorbital, nasolabial folds) at baseline and weeks 4, 8, 16 for comparison
Matrixyl 3000 absorbs best on clean skin without residue from other products.
If stacking with GHK-Cu serum, apply GHK-Cu first and wait 2 minutes. Its lower molecular weight gives it faster dermal absorption.
Dispense 2 to 4 drops of your Matrixyl 3000 serum (aim for 3% complex concentration or higher). Apply in thin layers to target areas: around the eyes, forehead lines, nasolabial folds, and neck.
Wait 2 to 3 minutes for absorption before layering additional products.
Matrixyl 3000 is compatible with hyaluronic acid, niacinamide, and vitamin C serums in the same routine.
If your skin is sensitive, start once daily in the PM for the first 2 weeks.
If using a retinoid in your routine and experiencing irritation from layering, separate them: Matrixyl 3000 in the AM, retinoid in the PM.
Do not apply within 48 to 72 hours after chemical peels (glycolic above 20%, TCA). Wait for full barrier recovery.
Store opened serums at 2 to 8 degrees Celsius away from direct light. Sealed commercial products are stable at room temperature. Use opened serums within 6 months.
Same 3–4% complex concentration product; enhanced penetration to viable dermis via microneedle-created microchannels
Apply to skin immediately after dermaroller (0.25–0.5 mm) or microneedling session while microchannels are open. Community reports suggest enhanced and faster results. No published clinical trial. Compromised barrier increases absorption of ALL product ingredients including excipients: use only well-characterized, preservative-minimal formulations. Allow full barrier recovery (24–48h) before resuming standard routine.
Same concentration; electrophoretic enhancement targets hydrophilic peptide fraction
Experimental and marginal: palmitoyl conjugation already optimizes passive lipophilic diffusion through stratum corneum; iontophoresis provides limited additional benefit over a well-formulated topical serum
Synergistic collagen stimulation: Pal-GHK (matrikine pathway) and GHK-Cu (copper-mediated enzymatic pathway) activate complementary fibroblast signaling. Shared GHK tripeptide backbone. Apply GHK-Cu first (lower molecular weight, higher diffusion rate).
GHK-Cu serum first, allow 2 min absorption, then Matrixyl 3000 serum; AM and PM
SNAP-8 inhibits acetylcholine release at neuromuscular junctions to relax expression lines; Matrixyl 3000 stimulates matrix production: complementary non-competing mechanisms targeting dynamic and static wrinkles respectively
SNAP-8 in PM application only; Matrixyl 3000 AM and PM
Additive procollagen stimulation: original Matrixyl targets a different collagen fragment pathway (procollagen C-propeptide / Pal-KTTKS) vs. Matrixyl 3000 (GHK matrikine). Together provide broader matrix signaling coverage.
Argireline (acetyl hexapeptide-3) inhibits muscle contraction to reduce dynamic wrinkles; Matrixyl 3000 restores and builds matrix volume: complementary approach for multi-vector anti-aging
Compromised skin barrier post-peel may alter peptide absorption kinetics and cause irritation at application site; wait 48–72 hours after any peel-strength exfoliant before resuming
Long-term steroid use thins the dermis and reduces the collagen substrate available for Matrixyl 3000-stimulated matrix remodeling; may blunt efficacy of peptide protocol
Theoretical interaction with Pal-GQPR anti-inflammatory (IL-6 / NF-kB) pathway; no clinical combination data; use with caution
Pricing updated 2026-04-09
The most relevant safety consideration is product quality, not the peptides themselves. Commercial formulations vary wildly in actual Matrixyl 3000 concentration, and products with undisclosed percentages or the peptides listed near the bottom of the INCI list may not contain enough active ingredient to match clinical trial conditions. For the peptides at tested concentrations: the CIR Expert Panel (Int J Toxicol 2018) assessed tripeptide-1, its fatty acyl derivatives, and palmitoyl tetrapeptide-7 as safe for use in cosmetics at current concentrations (typically below 10 ppm for individual peptides). Clinical studies report no significant adverse effects at the concentrations used. Mild temporary redness or tingling at the application site can occur, particularly in people with sensitive skin. This is most common during the first week of twice-daily use and typically resolves without intervention. Reducing to once-daily PM application for two weeks before ramping back up handles most cases. Allergic contact dermatitis is theoretically possible but hasn't been reported at meaningful rates in either the published literature or community forums. If you notice persistent redness, itching, or irritation that doesn't resolve within a few days, stop use and evaluate. Layering with strong chemical exfoliants requires caution. Applying Matrixyl 3000 within 48 hours of a glycolic acid peel (above 20%) or TCA peel can cause stinging and irritation because the compromised skin barrier alters absorption of the peptides and every other ingredient in the formulation. No systemic side effects are expected. The palmitoyl chains keep these peptides in the skin layers; transdermal absorption into systemic circulation is minimal (below 1%). Pregnant or breastfeeding individuals should avoid use. No safety data exists for this population. Children under 18 lack sufficient safety data as well. When to stop: persistent redness, itching, or signs of contact dermatitis that don't resolve after 3 to 5 days off. When to consult a dermatologist: any suspected allergic reaction, especially if facial swelling or widespread irritation develops.
Verify Matrixyl 3000 dosing and safety with a second opinion
No injection or sterility concerns (topical cosmeceutical). Quality risk is entirely formulation-concentration dependent: many commercial products list Matrixyl 3000 without % disclosure or near the bottom of the INCI list, indicating sub-effective concentrations. Sederma INCI names (palmitoyl tripeptide-1, palmitoyl tetrapeptide-7) should appear within the top 10 INCI ingredients for adequate dosing. Sederma recommends 2–4% complex; most clinical trial evidence used 3%.
| Test | When | Target |
|---|---|---|
| Skin patch test | Before first application | — |
| Visual skin assessment | Monthly during first 3 months | — |
Screen for contact sensitization to palmitoyl-GHK and palmitoyl-GQPR
Monitor for irritation or signs of contact dermatitis at application sites
No visible anti-aging changes expected. The peptide complex begins accumulating in the upper skin layers. Some users report an immediate smoothing or hydrating sensation from the serum vehicle itself.
Early improvements in skin texture and hydration may become noticeable. Pal-GHK is activating fibroblast collagen synthesis while Pal-GQPR begins reducing inflammatory mediators. Fine surface lines may start to soften.
Measurable wrinkle reduction becomes apparent. Manufacturer clinical data shows significant improvement by the 2-month mark, with up to 45% reduction in deep wrinkle surface area. Skin firmness and elasticity begin to improve as new collagen fibers mature.
Continued progressive improvement. Collagen remodeling deepens. Wrinkle density decreases further. The 6-month Sederma study reported up to 68% wrinkle surface area reduction and 46% decrease in wrinkle density at the extended timepoint.
Maintenance phase. Continued application sustains and slowly builds on results. Effects are cumulative and ongoing. If discontinued, wrinkle depth and skin texture gradually return toward baseline over 6-12 weeks.
Weeks 1 to 2: Nothing visible yet. The peptide complex is accumulating in the upper skin layers while fibroblast signaling gets started. Some people notice an immediate smoothing or hydrating feel from the serum base itself (usually glycerin or hyaluronic acid), but that's the vehicle, not the peptides working yet. Sensitive skin may pick up mild tingling in the first 10 to 15 minutes after application. It resolves on its own. Weeks 2 to 4: Skin texture and hydration start to shift. Pal-GQPR is dialing down IL-6 inflammatory signaling while Pal-GHK kicks fibroblast glycosaminoglycan and collagen synthesis into gear. Fine surface lines may begin softening with consistent twice-daily use. These early changes are subtle; you'll notice them more by touch than in a mirror. Weeks 4 to 8: This is the clinical endpoint window. Sederma's 2-month RCT measured 45% reduction in deep wrinkle surface area, 17.1% decrease in wrinkle volume, and roughly 20% improvement in skin tonicity. Community members consistently flag this as the period where results become visible in photographs. New collagen fibers are maturing and the anti-inflammatory arm has had enough time to slow MMP-driven breakdown. Weeks 8 to 16: Progressive improvement continues. Collagen remodeling deepens as fibers mature and thicken. The Sederma 6-month dataset reported up to 68% wrinkle surface area reduction and 46% decrease in wrinkle density. The independent 2024 RCT [1] confirmed sustained mRNA upregulation at 12 weeks. Skin firmness becomes apparent to other people, not just you in the mirror. Week 16 and beyond: Maintenance territory. Gains hold with continued application and slowly build. If you stop, wrinkle depth and skin texture drift back toward baseline over 6 to 12 weeks as collagen turnover loses the extra stimulation. Long-term users applying once or twice daily report sustained results at 12 months and beyond without hitting a plateau. The cycling break (2 weeks off after 16 on) is optional; no receptor desensitization has been documented.
Peptide complex accumulating in upper skin layers. Fibroblast signaling initiation. No structural changes detectable: collagen synthesis and matrix remodeling take weeks.
No visible anti-aging change expected. Some users report an immediate hydrating or smoothing sensation from the serum vehicle (typically glycerin/HA base).
Pal-GQPR reducing IL-6 inflammatory signaling; Pal-GHK activating fibroblast GAG and collagen synthesis. Early surface line softening possible with new glycosaminoglycan production.
Skin texture and hydration improvements become noticeable; fine surface lines may begin to soften with consistent twice-daily use
Primary clinical endpoint period. Sederma 2-month RCT: 45% deep wrinkle surface area reduction, 17.1% wrinkle volume decrease, ~20% increase in skin tonicity.
Visible wrinkle reduction and skin firmness improvement. Most community members report this as the milestone where results become objectively noticeable in photographs.
Continued new collagen fiber synthesis and maturation. Sederma 6-month data: up to 68% wrinkle surface area reduction and 46% wrinkle density decrease at extended timepoint.
Continued progressive improvement; skin firmness and wrinkle density reductions become apparent to others. 2024 PMID 38932444 at 12 weeks confirms sustained mRNA upregulation.
Cumulative gains sustained with continued application. If discontinued, skin texture and wrinkle depth gradually return toward baseline over 6–12 weeks as ongoing collagen turnover is no longer stimulated.
Long-term users continue 1–2× daily maintenance; many report sustained results at 12+ months without observed plateau. Cycling break is optional: no physiological requirement documented.
Source: Estimated ~6 hours topical half-life based on Sederma product data. No formal systemic pharmacokinetic studies exist: Matrixyl 3000 is a topical cosmeceutical with minimal transdermal absorption. The palmitoyl chains enhance skin layer retention but do not promote significant systemic bioavailability.
Loading the interactive decay curve.
Matrixyl 3000 is a patented cosmeceutical ingredient (Sederma/BASF, patent WO 2005/048968). It is not FDA-approved for any medical indication and does not hold drug status in any jurisdiction. The FDA classifies topical peptide complexes like this as cosmetic ingredients, not pharmaceuticals. The CIR Expert Panel reviewed the safety of tripeptide-1, its acyl derivatives, and palmitoyl tetrapeptide-7 in 2018 (Int J Toxicol, doi:10.1177/1091581818807863) and confirmed they are safe as used in current cosmetic concentrations. No WADA restriction applies. Matrixyl 3000 is topical with negligible systemic absorption. Matrixyl 3000 products are widely available over the counter worldwide without prescription. The ingredient is sold to cosmetic formulators by Sederma (now BASF) and appears in hundreds of commercial anti-aging products. No pending regulatory changes affect its availability. This content is for informational purposes only and does not constitute medical advice. Consult a dermatologist before starting any new skincare regimen, especially if you have a history of contact dermatitis or are pregnant or breastfeeding.
Peptide Schedule Research TeamReviewed Apr 20269 Citations
